Nolpaza tablets gastro-resistant

البلد: أرمينيا

اللغة: الإنجليزية

المصدر: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

خصائص المنتج خصائص المنتج (SPC)
16-04-2021

العنصر النشط:

pantoprazole (pantoprazole sodium sesquihydrate)

متاح من:

KRKA d.d.

ATC رمز:

A02BC02

INN (الاسم الدولي):

pantoprazole (pantoprazole sodium sesquihydrate)

جرعة:

40mg

الشكل الصيدلاني:

tablets gastro-resistant

الوحدات في الحزمة:

(14/1x14/) in blister, (28/2x14/) in blister, (56/4x14/) in blister

نوع الوصفة الطبية :

Prescription

الوضع إذن:

Registered

تاريخ الترخيص:

2021-04-16

خصائص المنتج

                                PI_Text001952_1
– Updated:
Page 1 of 11
1.
NAME OF THE MEDICINAL PRODUCT
Nolpaza
®
20 mg gastro-resistant tablets
Nolpaza
®
40 mg gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 20 mg gastro-resistant tablet contains 20 mg pantoprazole as
22.55 mg pantoprazole sodium
sesquihydrate.
Each 40 mg gastro-resistant tablet contains 40 mg pantoprazole as
45.10 mg pantoprazole sodium
sesquihydrate.
Excipient:
Each 20 mg gastro-resistant tablet contains 18 mg sorbitol (E420).
Each 40 mg gastro-resistant tablet contains 36 mg sorbitol (E420).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablet
Light yellowish brown, oval, slightly biconvex film-coated tablets.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
_Adults and adolescents 12 years of age and above_
-
Symptomatic gastro-oesophageal reflux disease.
-
For long-term management and prevention of relapse in reflux
oesophagitis.
-
Reflux oesophagitis
_Adults_
-
Prevention of gastroduodenal ulcers induced by non-selective
non-steroidal anti-inflammatory
drugs (NSAIDs) in patients at high risk with a need for continuous
NSAID treatment (see
section 4.4).
-
Eradication of _Helicobacter pylori _(_H. pylori_) in combination with
appropriate antibiotic therapy
in patients with _H. pylori _associated ulcers.
-
Gastric and duodenal ulcers.
-
Zollinger-Ellison syndrome and other pathological hypersecretory
conditions.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The tablets should not be chewed or crushed, and should be swallowed
whole 1 hour before a meal
with some water.
_RECOMMENDED DOSE_
_ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND ABOVE_
CONFIDENTIAL
Nolpaza gastro-resistant tablets 20 mg, 40 mg
VOL: 1; P: 30 / 64
PI_Text001952_1
– Updated:
Page 2 of 11
Symptomatic gastro-oesophageal reflux disease
The recommended oral dose is one Nolpaza 20 mg gastro-resistant tablet
per day. Symptom relief is
generally accomplished within 2–4 weeks. If this is not sufficient,
symptom relief will normally be
achieve
                                
                                اقرأ الوثيقة كاملة
                                
                            

مستندات بلغات أخرى

نشرة المعلومات نشرة المعلومات الروسية 16-04-2021

تنبيهات البحث المتعلقة بهذا المنتج

عرض محفوظات المستندات